Source: XTM.
  • XTM (PAID) has welcomed People2.0 to its Today Financial platform for earned wage access and to its Timely Staff Management platform for shift management and staff callouts
  • People2.0 is the world’s leading enabler of global, mobile, flexible, and remote work arrangements
  • The partnership aims to greatly improve the quality of the employee experience through automation and instant earnings access
  • XTM is a fintech innovator and leader in on-demand pay whose partners include Earls, Maple Leaf Sports & Entertainment, Cactus Club, Marriott Hotels and Live Nation
  • XTM (PAID) opened today at $0.18

XTM (PAID) has onboarded People2.0 to its services.

These include the Today Financial platform for earned wage access and the Timely Staff Management platform for shift management and staff callouts.

People2.0 is a global enabler of mobile, remote, and flexible work arrangements. The company offers a global ecosystem where talent suppliers can engage any category of worker in any work arrangement.

The partnership is intended to improve the employee experience through digital automation, featurization, and instant access to earnings.

XTM is a fintech innovator and leader in on-demand pay whose partners include Earls, Maple Leaf Sports & Entertainment, Cactus Club, Marriott Hotels and Live Nation. Its Today Financial platform is used by thousands of businesses across Canada and the U.S.

XTM (PAID) opened today at $0.18.

For full disclaimer information, please click here.


More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.